The YC W2026 batch contained a perfect irony: ARC Prize Foundation, which runs ARC-AGI. Ndea, François Chollet's $43M lab, which designed ARC-AGI. And Confluence Labs, which just scored 97.9% on ARC-AGI-2, a benchmark specifically built to resist LLM shortcuts. All in the same cohort. The benchmark, its creator, and its destroyer, sharing office hours at Y Combinator.
That's not a coincidence. It's a signal that the AI reasoning frontier just moved. Fast.
What Confluence Labs Does
Confluence Labs is an AI research lab focused on what founder Brent Burdick calls "learning efficiency", specifically, the ability for AI systems to solve problems in domains where training data is scarce. Drug design. Hardware engineering. Physics research. The places where modern LLMs are nearly useless because there's no ocean of internet text to memorize.
Their proof of concept: a system that scores 97.9% on ARC-AGI-2 at roughly $12 per task. For context, ARC-AGI-2 was designed by Chollet precisely to resist the pattern-matching tricks that make GPT-4 look smart on standardized tests. The benchmark requires genuine few-shot reasoning, you get 3, 5 input/output pairs and must figure out the transformation rule from scratch. Humans score around 60%. Top LLMs were below 5% before Confluence published their approach.
The business model is still forming, they're in research-lab mode, recruiting domain experts in biology, materials science, and hardware. But the commercial thesis is clear: if you can make AI that actually reasons in data-sparse environments, you can charge a lot for it in industries where a single correct hypothesis is worth millions.
How It Works: Program Synthesis + LLM Orchestration
The core insight is elegant. LLMs are terrible at directly answering "what transformation turns input grid A into output grid B?" But LLMs are exceptional at writing code. So instead of asking the model to solve the problem, Confluence asks it to write a program that solves the problem.
This is program synthesis, a field that's been around since the 1970s, but weaponized with modern LLMs as the code generator. The system works like this:
- Input: A set of 3, 5 (input, output) example pairs and a test input.
- Generate: An LLM (Google Gemini in their open-sourced solver) writes Python code that implements the transformation:
def transform(grid): ... - Execute: The code runs in a sandboxed E2B environment against the known examples to verify correctness.
- Refine: If the code fails or produces wrong output, the error is fed back to the LLM for up to 10 refinement loops per agent.
- Vote: 12 agents run in parallel. Whichever solution passes the most verification checks wins. Up to 132 sandboxes run concurrently.
The architecture isn't magical, it's systematic. By converting a reasoning problem into a code generation + execution problem, they sidestep the LLM's inability to hold complex spatial reasoning in its context window. The code does the heavy lifting; the LLM generates and refines hypotheses.
What's clever is the verification loop. Traditional program synthesis requires formal specifications. Confluence uses the provided examples as the spec, and code execution as the oracle. Wrong output? The error message feeds back into the prompt. Each loop narrows the hypothesis space.
The Tech Stack
Their open-sourced ARC-AGI-2 solver on GitHub reveals the bones:
- LLM backbone: Google Gemini API (large context, strong at code generation)
- Sandbox execution: E2B (managed sandboxes, each isolated Python environment)
- Concurrency: 132 simultaneous sandboxes, 12 agents per task
- Refinement: Up to 10 loops per agent before abandoning
- Runtime: 12-hour wall clock timeout for full evaluation runs
The proprietary layer, the part not in the GitHub repo, is presumably the prompt engineering, the refinement heuristics, and critically, how they plan to adapt this architecture for scientific domains beyond grid puzzles.
Difficulty Score
| Dimension | Score | Why |
|---|---|---|
| ML / AI | 9/10 | Frontier research combining program synthesis with LLM orchestration. Reproducing 97.9% requires careful prompt engineering and multi-agent tuning. |
| Data | 6/10 | ARC-AGI-2 is public. The hard data problem is building domain-specific datasets for drug design and hardware, that's a 9/10 problem on its own. |
| Backend | 7/10 | Multi-agent orchestration at scale, sandbox lifecycle management, result aggregation, cost tracking. Non-trivial but uses well-understood patterns. |
| Frontend | 2/10 | Research lab. They probably have a dashboard nobody shows to investors. |
| DevOps | 7/10 | 132 concurrent sandboxes requires careful resource management. E2B abstracts some of this, but production reliability at scale is real engineering work. |
The Moat: What's Hard, What's Not
What's easy to replicate: The core ARC-AGI-2 solver is open-sourced. You can clone their GitHub, plug in a Gemini API key, and reproduce the 97.9% result. The architecture is documented. The concept of "LLM writes code, code gets executed, errors feed back" is not proprietary.
What's hard to replicate: Three things.
First, domain translation. Going from "this works on grid puzzles" to "this works on protein folding hypothesis generation" requires intimate domain knowledge that Confluence has to acquire through scientific collaborations. You can't prompt-engineer your way into understanding what makes a drug candidate viable.
Second, research credibility compounding. The team that solved ARC-AGI-2 has a credibility advantage that makes it easier to attract the PhD biologists and hardware engineers needed to build the next layer. Benchmarks matter in science recruiting.
Third, the compute economics. At $12/task, this approach is viable for high-value scientific hypotheses, not for mass-market SaaS. Whoever figures out how to get cost to $0.50/task while maintaining accuracy builds a very different business. That optimization work is ongoing and non-trivial.
The honest assessment: the technical moat is modest right now. The scientific network moat is where this becomes defensible. Drug companies don't let just anyone run experiments against their proprietary compound libraries. If Confluence gets those partnerships first, latecomers face locked doors.
Replicability Score: 62 / 100
The core architecture is open-source. A strong engineering team with a Gemini API key and an E2B account can reproduce the ARC-AGI-2 result in a week. But "solving a reasoning benchmark" and "accelerating drug discovery" are separated by a chasm of domain expertise, scientific trust, and proprietary data access that takes years to bridge. The ML architecture earns a 40; the go-to-market earns an 80. Average: 62. You can clone the code. You can't clone the scientific relationships.
The Bigger Question
Here's what's actually interesting about Confluence: they're one of the few YC W2026 companies making a real bet on symbolic + neural hybrid approaches rather than just "more tokens, bigger model." The AI field has broadly acknowledged that neural scaling alone hits diminishing returns, which means the companies that figured out how to combine LLMs with structured reasoning are well-positioned for the next 24 months.
Whether drug discovery is the right first market is debatable. The regulatory cycles are long. The feedback loops are brutal. A wrong hypothesis in drug design doesn't generate an error message in 30ms, it generates a failed clinical trial in five years. That's a hard environment for iterative refinement.
Hardware engineering is a more interesting near-term bet. A chip design hypothesis can be simulated in hours. If Confluence can show that their program synthesis approach speeds up VLSI design iteration, they'll have a paying customer in every semiconductor company desperate for faster tape-outs.
Watch for their first commercial partnership announcement. If it's pharma, they're playing a long game. If it's semiconductor or materials science, they might be shipping meaningful revenue in 18 months.